project id: TCGA-PRAD; case submitter id: TCGA-ZG-A8QZ; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.41; rna integrity number: 8.0; age at index: 65; days to birth: -23980; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1948; age at diagnosis: 23980; ajcc clinical m: M0; ajcc clinical t: T2a; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 308.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 322; initial weight: 110.0; sample id: 1a2cf323-2c13-4ffb-91f7-1a6a3b627012; sample submitter id: TCGA-ZG-A8QZ-01A; portion id: 42dc7f3a-929e-4e7c-b3b2-4c5b04ff3c7b; portion submitter id: TCGA-ZG-A8QZ-01A-11; slide id: 9a8d8289-1454-4b4c-ae31-305a5464bb27; slide submitter id: TCGA-ZG-A8QZ-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 20.0; percent tumor cells: 60.0; percent tumor nuclei: 80.0; section location: TOP;